Drug Research
The Medicines Company introduces new Cleviprex formulation
The Medicines Company has launched a new twelve hour formulation for the FDA approved Cleviprex Injectable Emulsion.Cleviprex is an intravenous dihydropyridine calcium channel blocker, which helps in reduction of blood pressure when oral therapy is not feasible. ...
Drug Research
Theraclone doses first patient in Phase 1 TCN-032 drug trial
Theraclone Sciences has dosed first patient in a randomized, double-blind, dose-escalation Phase 1 trial investigating TCN-032 as a treatment for influenza A virus. TCN-032 was discovered utilizing Theraclone's I-STAR platform.The trial aims to investigate...
Drug Research
FDA approves Amphastar Enoxaparin Sodium Injection
The US Food and Drug Administration has approved Amphastar Pharmaceuticals' abbreviated new drug application for Enoxaparin Sodium Injection.The approval has been granted for 100mg/ml and 150mg/ml strengths. Enoxaparin Sodium Injection is the generic version...
Drug Research
Dey Pharma to provide EpiPen Auto-Injectors
Mylan's subsidiary Dey Pharma is set to offer EpiPen 2-Pak and EpiPen Jr 2-Pak (epinephrine) Auto-Injector 0.3/0.15mg exclusively for the emergency treatment of severe allergic reactions (anaphylaxis). EpiPen and EpiPen Jr Auto-Injectors are intended for...
Drug Research
Unilife develops safety syringe to reconstitute lyophilized drugs
Unilife has developed Unifill EZMix multiple-chamber ready-to-fill (prefilled) safety syringe for lyophilized drugs and vaccines requiring reconstitution.Unifill EZMix syringes comprises two or more drug containers within a single glass barrel to store a combination of liquid stable or lyophilized...
Drug Research
Allos recruits first patient in Phase 3 PTCL drug trial
Allos Therapeutics has recruited first patient in a Phase 3 multi-center, randomized, open-label (PDX-017) Phase 2 trial investigating Folotyn (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL). Folotyn is approved in the...
Drug Research
Abbott two new strengths of CPP drug gets FDA nod
Abbott has received the US Food and Drug Administration (FDA) approval for two new strengths of Lupron Depot-PED (leuprolide acetate for depot suspension) to treat children with central precocious puberty (CPP). The application was submitted...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read